Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Centessa Pharmaceuticals
Biotech
Anaptys picks up rival to Biogen autoimmune asset from Centessa
Anaptys is picking up a challenger to Biogen's late-phase lupus candidate, paying Centessa $7 million upfront for rights to a preclinical prospect.
Nick Paul Taylor
Nov 28, 2023 6:30am
Elevated liver enzymes force Centessa to drop another asset
Aug 10, 2022 9:34am
Centessa dumps top program after evidence of tolerability issues
Jun 2, 2022 11:25am
Centessa hemophilia drug shows reduction of bleeding in phase 2
Sep 9, 2021 9:47am
Centessa Pharma eyeing $250M IPO to fund early drug development
May 24, 2021 11:00am
Salter-Cid joins former BMS peer at Flagship—Chutes & Ladders
May 14, 2021 9:30am
